Eli Lilly has agreed to buy DICE Therapeutics in a $2.4 billion cash deal that reflects Lilly’s ambitions in immunology, a hot market where the company has lagged behind its coompetitors.
June 20, 2023 - 14:47
By Pharos Investment Advisors Comments are Off
Eli Lilly has agreed to buy DICE Therapeutics in a $2.4 billion cash deal that reflects Lilly’s ambitions in immunology, a hot market where the company has lagged behind its coompetitors.
Regulated by Hellenic Capital Market Commission
with Registration Number 5/700/10.12.2014

Copyright 2023©. All Rights Reserved